Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Short-term Investments (2019 - 2025)

KalVista Pharmaceuticals' Short-term Investments history spans 6 years, with the latest figure at $89.0 million for Q2 2025.

  • On a quarterly basis, Short-term Investments fell 50.17% to $89.0 million in Q2 2025 year-over-year; TTM through Apr 2025 was $89.0 million, a 50.17% decrease, with the full-year FY2025 number at $89.0 million, down 50.17% from a year prior.
  • Short-term Investments hit $89.0 million in Q2 2025 for KalVista Pharmaceuticals, up from $86.0 million in the prior quarter.
  • Over the last five years, Short-term Investments for KALV hit a ceiling of $198.3 million in Q2 2021 and a floor of $32.6 million in Q1 2021.
  • Historically, Short-term Investments has averaged $98.7 million across 4 years, with a median of $89.0 million in 2025.
  • Biggest five-year swings in Short-term Investments: surged 281.97% in 2021 and later tumbled 50.17% in 2025.
  • Tracing KALV's Short-term Investments over 4 years: stood at $198.3 million in 2021, then plummeted by 77.06% to $45.5 million in 2023, then skyrocketed by 89.03% to $86.0 million in 2024, then increased by 3.47% to $89.0 million in 2025.
  • Business Quant data shows Short-term Investments for KALV at $89.0 million in Q2 2025, $86.0 million in Q4 2024, and $94.2 million in Q4 2024.